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Aims There is debate about the optimum algorithm for cardiovascular disease (CVD) risk estimation. We conducted
head-to-head comparisons of four algorithms recommended by primary prevention guidelines, before and after
‘recalibration’, a method that adapts risk algorithms to take account of differences in the risk characteristics of the
populations being studied.
...................................................................................................................................................................................................
Methods
and results
Using individual-participant data on 360 737 participants without CVD at baseline in 86 prospective studies from
22 countries, we compared the Framingham risk score (FRS), Systematic COronary Risk Evaluation (SCORE),
pooled cohort equations (PCE), and Reynolds risk score (RRS). We calculated measures of risk discrimination and
calibration, and modelled clinical implications of initiating statin therapy in people judged to be at ‘high’ 10 year
CVD risk. Original risk algorithms were recalibrated using the risk factor profile and CVD incidence of target popu-
lations. The four algorithms had similar risk discrimination. Before recalibration, FRS, SCORE, and PCE over-
predicted CVD risk on average by 10%, 52%, and 41%, respectively, whereas RRS under-predicted by 10%.
Original versions of algorithms classified 29–39% of individuals aged >_40 years as high risk. By contrast, recalibra-
tion reduced this proportion to 22–24% for every algorithm. We estimated that to prevent one CVD event,
it would be necessary to initiate statin therapy in 44–51 such individuals using original algorithms, in contrast to
37–39 individuals with recalibrated algorithms.
...................................................................................................................................................................................................
Conclusion Before recalibration, the clinical performance of four widely used CVD risk algorithms varied substantially. By con-
trast, simple recalibration nearly equalized their performance and improved modelled targeting of preventive action
to clinical need.
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Introduction
A key strategy in the primary prevention of cardiovascular disease
(CVD) is the use of risk prediction algorithms to target preventive
interventions on people who should benefit from them most.1,2 There
is, however, debate about the optimum algorithm for CVD risk estima-
tion. The 2013 guidelines of the American College of Cardiology/
American Heart Association (ACC/AHA)3,4 have recommended the
Pooled cohort equations (PCE). By contrast, the 2016 guidelines of the
European Society of Cardiology5 have recommended the Systematic
COronary Risk Evaluation (SCORE) algorithm.6,7 The Framingham risk
score (FRS)8 and the Reynolds risk score (RRS)9,10 have been recom-
mended by other North American guidelines.11,12 Additional algo-
rithms have been recommended by further guidelines.13,14
Such contrasting recommendations may create confusion among
practitioners, potentially reflecting uncertainty about the perform-
ance of different algorithms under different circumstances. For ex-
ample, because CVD event rates and average risk factor levels vary
over time and place, algorithms developed in one population may
not predict the correct risk in the target population being screened
(i.e. they may not be well ‘calibrated’15,16). Furthermore, although
most CVD risk algorithms include information on a common set of
risk factors, algorithms can differ owing to differences in the exact set
of risk factors included, mathematical formulations used, and defini-
tions of CVD outcomes employed. Hence, use of different algorithms
as currently recommended could lead to varying clinical performance
and uneven efficiency in allocating preventive interventions. Only few
and relatively small studies have, however, provided head-to-head
comparisons of different risk prediction algorithms recommend by
primary prevention guidelines for allocation of statin therapy.17–19
Despite some previous attempts to adjust risk algorithms to local
and/or contemporary circumstances (i.e. ‘recalibration’),17,20 few
have compared recalibrated versions of algorithms systematically
across many populations.
Our study, therefore, aimed to address two sets of questions.
First, how do risk prediction algorithms differ in term of predictive ac-
curacy and clinical performance when evaluated in the same popula-
tion? We chose algorithms that have been recommended by a
guideline statement and could be evaluated with the information
available in our consortium dataset. Hence, we conducted head-to-
head comparisons of original versions of four risk algorithms (FRS,
SCORE, PCE, and RRS), evaluating them using measures of predictive
accuracy (e.g. discrimination, calibration) as well as clinical perform-
ance (e.g. we modelled the potential impact of initiating statin therapy
as recommended by primary prevention CVD guidelines3,4). The se-
cond set of questions is: what is the clinical impact of adjusting these
algorithms to local and contemporary circumstances, and how do
they then compare to each other? To address them, we recalibrated
these algorithms using CVD event rates and risk factor values of the
target populations, and compared the performance of the original
and recalibrated versions of algorithms across multiple settings.
Methods
Data sources
We analysed data from the Emerging Risk Factors Collaboration (ERFC),
a consortium of prospective cohort studies with information on a variety
of risk factors.21 Prospective cohort studies were included in this analysis
if they met all the following criteria: (i) had not contributed data to the de-
velopment of any of the risk prediction algorithms studied in this ana-
lysis4,6,8–10; (ii) had recorded information on risk factors necessary to
calculate algorithms [i.e. age, sex, smoking status, history of diabetes, sys-
tolic blood pressure, total and high-density lipoprotein cholesterol,
Equalization of four CVD algorithms 3
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ethnicity, and use of antihypertensive medications; Supplementary ma-
terial online, Table S1 and Supplementary material online, Appendix S1];
(iii) were approximately population based (i.e. did not select partici-
pants on the basis of having previous disease); (iv) had recorded cause-
specific deaths and non-fatal CVD events [i.e. non-fatal myocardial in-
farction (MI) or stroke] using well-defined criteria; and (v) had at least
1 year of follow-up after baseline. Details of contributing studies are in
Supplementary material online, Table S2 and Supplementary material
online, Appendix S2. All studies used definitions of non-fatal MI based
on World Health Organization (or similar) criteria and of non-fatal
stroke based on clinical and brain imaging features. In registering fatal
outcomes, all contributing studies classified deaths according to the
primary cause (or, in its absence, the underlying cause), and used
International Classification of Diseases, revisions 8, 9, and 10, coding to at
least three digits. Ascertainment of fatal outcomes was based on death
certificates, with 56 studies also involving review of medical records,
autopsy findings, and other supplementary sources. Supplementary
material online, Table S3 provides International Classification of
Diseases (ICD) codes used to define outcomes used in each CVD risk
prediction algorithm.
Statistical analysis
Analyses included participants aged between 40 and 79 years, excluding
those with a known history of CVD at baseline [i.e. coronary heart dis-
ease (CHD), other heart disease, stroke, transient ischaemic attack, per-
ipheral vascular disease, atrial fibrillation, heart failure, or any
cardiovascular surgery], as defined by each study.21,22 For each partici-
pant, we used original versions of FRS, SCORE, PCE, and RRS to calculate
the predicted 10 year risk of CVD events (Supplementary material online,
Appendix S1). To enable comparison with the three other risk prediction
algorithms evaluated in this study, we used a rescaled version of the FRS
algorithm which predicts non-fatal MI, fatal CHD, or any stroke (rather
than the broader CVD outcome it was originally derived for).8 For
SCORE, we used relevant high or low-risk versions depending on the
geographical location of the cohort as recommended by the ESC guide-
lines.5 Analyses involving RRS were performed in a subset of participants
who had information available on C-reactive protein, family history of
premature MI, and HbA1c (if female and with diabetes) (Supplementary
material online, Table S1).
To help provide systematic evaluation of the four risk algorithms to
predict relevant CVD endpoints, we used the following outcome defini-
tions. The principal outcome was the composite of CVD events during
the initial 10 year period of follow-up as defined by each algorithm (‘the
algorithm-specific outcome’): first onset of non-fatal MI, fatal CHD, or
any stroke for FRS and PCE; non-fatal MI, fatal CHD or any stroke, coron-
ary revascularization, or any CVD death for RRS; fatal CVD for SCORE
(Supplementary material online, Table S3). The secondary outcome was a
‘common’ CVD outcome, defined as the composite of non-fatal MI, fatal
CHD, or any stroke, adopting the definition of the 2013 ACC/AHA
guidelines (and used by PCE and FRS).4 Outcomes were censored if a
participant was lost to follow-up, died from non-CVD causes, or reached
10 years of follow-up. Participants contributed only the first non-fatal or
fatal CVD outcome (i.e. deaths preceded by non-fatal CVD events were
not included) except in the case of the SCORE-specific outcome, for
which all fatal CVD events were included.
We assessed risk discrimination using the C-index which estimates the
probability of correctly predicting who will have a CVD event first in a
randomly selected pair of participants.23 The C-index calculation was
stratified by sex and involved a two-stage approach, with estimates calcu-
lated separately within each study before pooling across studies weighting
by the number of contributing events.24 We assessed calibration of risk
algorithms for each algorithm-specific outcome by comparing predicted
and observed risks calculated for groups of participants defined by 5 year
age categories and calculating goodness of fit tests.25 Supplementary ma-
terial online, Appendix S3 provides further details of the methods used to
assess calibration. We recalibrated each algorithm as shown in
Supplementary material online, Figure S1 and Supplementary material on-
line, Appendix S3. Our approach involved adaptation of original risk algo-
rithms using the risk factor profile and CVD incidence of target
populations. Recalibration to CVD incidence involved two approaches.
First, we recalibrated each algorithm to predict incidence of the endpoint
it was derived to predict (the algorithm-specific outcome). Second, to en-
able head-to-head comparisons, we recalibrated SCORE and RRS to the
common CVD outcome used by FRS and PCE, as mentioned above.
Only studies with at least 10 years of follow-up were used in analyses
involving recalibration, or assessment of calibration.
To assess the clinical implications of using different algorithms to initi-
ate statin therapy in those whose 10 year CVD risk exceeds a given
threshold (as recommended by several CVD primary prevention guide-
line statements1,3–5,12), we estimated the number of individuals who
would be eligible for treatment and the potential cases avoided. First, we
assumed CVD risk assessment for a population of 100 000 men and
women aged >_40 years without CVD at baseline and not already taking
statins or meeting guideline recommendations for statin treatment (i.e.
people without a history of diabetes or CVD and with low-density lipo-
protein (LDL) cholesterol <190 mg/dL).3 Second, we assumed the same
age structure of a standard population of the United States. Third, we
assumed age- and sex-specific incidence rates for CVD events as in the
current study. Fourth, we assumed statin allocation according to the
threshold of predicted 10 year CVD risk recommended by 2013 ACC/
AHA guidelines4 for first-onset fatal and non-fatal CVD events (i.e.
>_7.5%), or by the 2016 ESC Guidelines for fatal CVD (i.e. >_5%).5 Fifth,
we assumed CVD risk reductions of 20% with statin treatment in people
without a history of CVD, as reported by the Cholesterol Treatment
Trialists’ Collaboration.26 We also compared categorization of partici-
pants across different algorithms before and after their recalibration using
the net reclassification improvement (NRI).27
Analyses were performed using Stata version 14. P-values are
two-sided. The study was designed and conducted by this collabora-
tion’s academic coordinating centre, and was approved by the
Cambridgeshire Ethics Review Committee. The funders had no scien-
tific role in the study.
Results
We analysed data on 360 737 participants without prior CVD who
were recruited into 86 prospective cohorts between the years 1963
and 2003 (Supplementary material online, Table S2). The mean
(standard deviation) age at baseline was 59 (8) years; 53% were male.
Sixty-nine percent of the participants were recruited in European
countries, 18% in North America, and the remainder mostly in Japan
and Australia. Median (5th–95th percentile) follow-up was 10.2 (3.4–
21.3) years, and during the initial 10 years of follow-up (3.1 million
person-years at risk), 14 564 incident CVD events were recorded
according to our common and FRS/PCE CVD definition, including
9259 CHD events and 5305 stroke events. At baseline, the median
(5th–95th percentile) predicted 10 year CVD risks were 5.54% (1.02–
23.34%) using FRS, 2.49% (0.13–23.25%) using SCORE, and 6.43%
(0.69–33.33%) using PCE (Table 1). Baseline characteristics for the
subset of participants with information on the RRS are presented in
Supplementary material online, Table S4.
4 L. Pennells et al.
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Discrimination and calibration
When using algorithm-specific CVD outcomes, each algorithm pro-
vided broadly similar discrimination, with absolute C-index values
ranging from 0.7010 to 0.7605. The pooled cohort equations pro-
vided somewhat greater risk discrimination than FRS or SCORE for
all algorithm-specific outcomes, with differences in overall C-index
compared with FRS between 0.0039 and 0.0131 (P< 0.001 when
testing the null hypothesis of no difference between C-indices;
Figure 1). Differences were greater for women than men, but similar
among participants from European and North American cohorts
(Supplementary material online, Figure S2). A similar pattern was
observed in analyses restricted to participants with complete
data enabling calculation of RRS (Supplementary material online,
Figure S3). Differences in the C-index among algorithms were not
affected by study recruitment periods (Supplementary material on-
line, Figure S4).
For each algorithm-specific outcome, on average across cohorts
the predicted 10 year risk was 1.10 times observed risk for FRS, 1.52
for SCORE, 1.41 for PCE, and 0.90 for RRS (P< 0.0001 for goodness
of fit/calibration for all algorithms; Figure 2 and Supplementary mater-
ial online, Figures S5 and S6). On average the extent of relative mis-
calibration was similar in men and women, and across all ages for
SCORE and PCE (Supplementary material online, Figure S5) which
translated to greater discrepancy between absolute predicted and
observed risks at older ages when using these algorithms
(Supplementary material online, Figure S6). Framingham risk score
tended to over-predict in men and younger women but to under-
predict in older women. Reynolds risk score underestimated risk
somewhat in men, but on average was well calibrated in women
(Figure 2, Supplementary material online, Figures S5 and S6). The ex-
tent and direction of mis-calibration varied substantially across indi-
vidual cohorts, ranging from more than 50% underestimation to
>400% overestimation of risk (Supplementary material online, Figures
S7 and S8). Heterogeneity in calibration could not be systematically
explained by broad geographical region but was partially explained by
year of baseline screening (Supplementary material online, Figure S9).
After recalibration of algorithms to the incidence of the common
CVD outcome and risk factor distribution of the cohorts contributing
to the current analysis, the distribution of predicted 10 year CVD risk
was similar across the four algorithms we studied (Supplementary
material online, Figure S10), yielding good calibration for each algo-
rithm (Supplementary material online, Figure S11). Risk discrimination
did not change with recalibration since ranking of participant risk is
unaffected by the recalibration methods used (Supplementary mater-
ial online, Figure S1 and Appendix S3).
Estimates of clinical performance
We initially conducted modelling that: employed original versions of
the four CVD risk algorithms we studied; was weighted to represent
the age and sex distribution of a standard US population >_40 years;
focused on individuals not already taking or eligible for statin treat-
ment (i.e. people without a history of diabetes or CVD and with LDL
<190 mg/dL)3; and defined the threshold for initiation of statin treat-
ment as an absolute 10 year risk of >_7.5% for FRS, PCE, and RRS, and
>_5% for SCORE (‘high risk’).
Under this scenario, we estimated that the proportion of individu-
als classified as high-risk (i.e. eligible for statin treatment) was 32%
with FRS, 29% with SCORE, 39% with PCE, and 32% with RRS
(Supplementary material online, Table S5 and Figure 3). By contrast,
after recalibration (using algorithmic-specific CVD endpoints), FRS,
SCORE, PCE, and RRS predicted CVD outcomes more accurately,
classified lower proportions of people as high risk, and identified
higher proportions of CVD events among people classified as high
risk. After further recalibration to the common CVD endpoint, the
proportion of individuals classified as high risk lowered to a near uni-
form level (22%, 22%, 24%, and 23% with FRS, SCORE, PCE, and
RRS, respectively). Of those classified as high risk by the original ver-
sions of algorithms, 11% later developed a first CVD event within
10 years (i.e. the positive predictive value was 11%, 11%, 10%, and
11%, respectively). By contrast, it was 13% with the recalibrated algo-
rithms (Supplementary material online, Table S5).
Based on these estimates, we calculated that to prevent one CVD
event when using original versions of FRS, SCORE, PCE, or RRS it
would be necessary to initiate statin therapy in 46, 44, 51, or 45 indi-
viduals, respectively (following screening of 145, 150, 131, or 142
individuals, respectively; Figure 3 and Supplementary material online,
Table S5). By contrast, when using any of the recalibrated algorithms,
one CVD event could be prevented by initiating statin therapy in 38
participants (following screening of 174, 171, 160, or 165 individuals,
respectively). Similar findings to those observed above were noted in
analyses that used a range of treatment thresholds different from
those in current guidelines (Figure 3) with the divergent clinical per-
formance of original algorithms converging to become almost identi-
cal at any treatment threshold after recalibration to a common CVD
endpoint.
.................................................................................................
Table 1 Baseline characteristics and predicted
10 year cardiovascular disease risk relevant to
assessed algorithms
Baseline characteristic Mean (SD) or n (%)
Age at survey (years) 59 (8.0)
Males 189 342 (52.5%)
Current smoking 98 593 (27.3%)
History of diabetes 16 758 (4.6%)
Systolic blood pressure (mmHg) 132 (19)
Total cholesterol (mmol/L) 5.83 (1.08)
HDL cholesterol (mmol/L) 1.33 (0.38)
Total/HDL cholesterol ratio 4.50 (1.61)
Hypertension medication 37 960 (10.5)
Lipid lowering medication 7929 (5.1)
Predicted 10 year risk (%) median (5th–95th percentiles)
Framingham risk score (FRS) 5.54% (1.02–23.34)
Systematic COronary Risk
Evaluation (SCORE)
2.49% (0.13–23.25)
Pooled cohort equations (PCE) 6.43% (0.69–33.33)
Data are from 86 cohorts with 360 737 participants and 23 563 CVD events
(14 538 occurring within 10 years). Versions of FRS and PCE used predict risk of
fatal or non-fatal CVD, SCORE predicts risk of fatal CVD.
HDL, high-density lipoprotein.
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..We then modelled the concordance of statin treatment decisions
based on use of these algorithms. Before recalibration, 41% of all indi-
viduals were at high risk with at least one of the four algorithms and
58% of these (24% of all individuals) were at high risk with all four. By
contrast, after recalibration to our common CVD outcome, 28% of
individuals were at high risk with at least one algorithm and 63% of
these (18% of all individuals) were at high risk with all four
(Supplementary material online, Figure S12). Discordance in treat-
ment decisions before recalibration tended to be greatest when
comparing SCORE to the other algorithms (Figure 4). For example, in
pairwise comparisons between FRS and SCORE, in every 100 000
people screened 36 794 would be classified as high risk with either
FRS or SCORE and 24 157 (66% of these) would be classified as high
risk with both FRS and SCORE. By contrast, after recalibration,
18 716 (76%) of the 24 708 individuals at high risk with either FRS or
SCORE would be at high risk with both algorithms (Figure 4). This
greater concordance between algorithms in identifying those at high
risk was also illustrated by a decrease in the NRI among both cases
and event-free participants after recalibration (Supplementary mater-
ial online, Table S6) and greater agreement between the absolute risk
predictions (Supplementary material online, Figure S13).
Discussion
In an analysis of individual-participant data on over 350 000 people
without a history of CVD at baseline, we systematically evaluated
several risk algorithms recommended by North American and
European guidelines for primary prevention of CVD. Our study’s
main finding was that the clinical performance of four widely used risk
algorithms varied substantially, predominantly due to differing extent
of calibration. By contrast, we observed only slight differences among
the algorithms in relation to risk discrimination (a measure of predict-
ive accuracy that is not influenced by the extent of model calibration).
After recalibration, however, the performance of the four algorithms
was essentially equalized. Our modelling suggested, therefore, that
targeting of CVD preventive action to clinical need would improve
considerably due to higher accuracy of individual risk predictions. A
key implication of these results is that CVD primary prevention
guidelines should shift away from debates about the relative merits of
particular risk algorithms and, instead, achieve consensus about the
need for more widespread use of any recalibrated algorithm.
Our findings have suggested that effective recalibration can be
achieved through the use of simple methods that can be applied using
FRS
SCORE
PCE
FRS
SCORE
PCE
FRS
SCORE
PCE
0.7194 (0.7154, 0.7234)
0.7194 (0.7154, 0.7234)
0.7232 (0.7193, 0.7272)
0.7474 (0.7421, 0.7527)
0.7576 (0.7524, 0.7628)
0.7605 (0.7554, 0.7657)
0.7258 (0.7222, 0.7294)
0.7298 (0.7262, 0.7333)
0.7332 (0.7297, 0.7368)
Ref
0.0000 (-0.0015, 0.0015)
0.0039 (0.0022, 0.0055)**
Ref
0.0102 (0.0081, 0.0123)**
0.0131 (0.0107, 0.0156)**
Ref
0.0040 (0.0026, 0.0054)**
0.0074 (0.0059, 0.0089)**
-0.01 0 0.01 0.02
Fatal and non-fatal 
CVD: 
PCE definition
Fatal CVD only: 
SCORE definition
Fatal and non-fatal 
CVD: 
RRS definition
RRS
RRS
RRS
0.7010 (0.6950, 0.7069)
0.7520 (0.7438, 0.7601)
0.7128 (0.7074, 0.7182)
0.0017 (-0.0011, 0.0044)
0.0081 (0.0041, 0.0121)**
0.0045 (0.0020, 0.0070)**
Absolute C-index value
for relevant endpoint 
and dataset (95% CI)
Change in C-index 
vs. FRS 
(95% CI)
Analysis based on 86 cohorts complete for estimation of FRS, SCORE and PCE 
Analysis based on 39 cohorts complete for estimation of RRS 
Improved 
discrimination vs FRS
Reduced 
discrimination vs FRS
Change in C-index vs. FRS (95% CI)
CVD outcome used in 
calculation of C-index
Figure 1 Discrimination abilities of original versions of three risk prediction algorithms compared with the Framingham risk score using alternative
CVD definitions. Number of events observed according to CVD definitions used by the Pooled Cohort Equations, the Systematic COronary Risk
Evaluation and the Reynolds Risk Score respectively were 14 564, 7433 and 17 642. Equivalent event numbers in the subset of participants with com-
plete data for estimation of the Reynolds Risk Score were 6670, 2966 and 7953 respectively. FRS, Framingham risk score; PCE, pooled cohort equa-
tions; RRS, Reynolds risk score; SCORE, Systematic COronary Risk Evaluation. *P < 0.05; **P < 0.001.
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aggregate level data on CVD event rates and average risk factor
values for a target population to be screened. To scale this ap-
proach for clinical and public health purposes, cardiovascular
bodies might facilitate the collation and regular updating of national
and regional age- and sex-specific CVD event rates and risk factor
data, including for particular geographical areas and ethnic groups
with distinctive CVD event rates and risk factors values. This infor-
mation could then be embedded in user-friendly risk prediction
tools (e.g. online risk calculators or electronic health records sys-
tems), enabling regular and simple recalibration, as previously
described.28,29 An alternative approach is the periodic develop-
ment of new risk algorithms, although it would be more costly and
time-consuming than recalibration because it entails launch of large
new cohort studies and their long-term follow-up.
In contrast with previous analyses of simulated data, studies in
single populations, or comparisons of risk scores without
recalibration,17–20,30–35 our study directly compared original and
recalibrated versions of four algorithms used across many different
populations, providing the first demonstration of the extent of CVD
risk prediction improvement achievable through recalibration. For
example, following recalibration we observed that the proportion of
individuals classified as high risk reduced from about 40% to 23%, and
the number of individuals needed to initiate statin therapy to prevent
one event reduced from between 44–51 to around 38. However,
our modelling reflects the average improvement that can be achieved
by recalibration across a set of different populations in which the ini-
tial extent and direction of mis-calibration varied substantially, partly
due to differences in baseline study year. Therefore, the clinical
improvement that could be achieved in countries or regions where
mis-calibration is more extreme could potentially be much greater.
Our approach to recalibration was distinctive in two ways. First, it
extended previous recalibration methods36 by using age groups in-
stead of categories of predicted risk, which allows direct application
to population data that are routinely recorded. Second, it differed
from other recalibration methods proposed for specific CVD risk
algorithms28,29 by providing a simpler procedure applicable to algo-
rithms derived using any type of statistical model. Because we studied
participant-level data from cohorts with prolonged follow-up, we
could adopt a uniform approach to statistical analyses and conduct
time-to-event analyses. To avoid providing over-optimistic assess-
ment of algorithm performance, we omitted cohorts that had previ-
ously contributed data to the derivation of the risk algorithms we
studied. Our clinical modelling was robust to different scenarios. The
generalizability of our findings was enhanced by inclusion of several
dozen population cohorts in 22 countries, mostly in Europe and
North America, and the broad range in baseline year of recruitment
across studies.
Our study had potential limitations. Because we used data from
the target cohorts themselves to recalibrate algorithms, the benefits
of recalibration could have been exaggerated (albeit in a manner that
would have affected each algorithm identically). Conversely, inaccur-
acy in CVD ascertainment in contributing cohorts would tend to
worsen the apparent performance of algorithms (again, affecting each
algorithm identically).37 Our modelling could have over-estimated
potential benefits of statin therapy because not all people eligible for
statins will receive them or be willing or able to take them. On the
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Figure 2 Observed and predicted 10-year cardiovascular risk using original version of prediction algorithms. Points presented in each plot are for
each 5-year age group between 40–44 to 75–79 years. Observed risk was calculated according to the CVD definition specific to each algorithm.
Assessment of the Framingham Risk Score, the Systematic COronary Risk Evaluation and the Pooled Cohort Equations was based on 223 663 partic-
ipants from 47 cohorts with at least 10 years of follow-up. Assessment of the Reynolds Risk Score was based on 91 008 participants from 27 cohorts
with at least 10 years of follow-up. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score; SCORE, Systematic
COronary Risk Evaluation.
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..other hand, greater clinical impact than suggested by our modelling
would be estimated if we had used less conservative assumptions
(e.g. use of more efficacious statin regimens or additional treatments;
longer time horizons; and lifestyle changes). We did not formally in-
corporate the impact of the potential hazards of statins into our
modelling. We had incomplete information on medication use (such
as statins and antihypertensive drugs) or cardiovascular intervention
(such as coronary revascularization) during follow-up, which may
have influenced our estimates of the observed CVD risk.
Revascularization endpoints may have been differentially recorded
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Figure 3 Estimated public health impact with screening using original and recalibrated cardiovascular disease risk prediction algorithms over a
range of risk thresholds in a standard US population of 100 000 people aged over 40 years. Cardiovascular disease includes fatal coronary heart dis-
ease, fatal, and non-fatal myocardial infarction and any stroke. FRS, Framingham risk score; PCE, pooled cohort equations; RRS, Reynolds risk score;
SCORE, Systematic COronary Risk Evaluation.
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across studies, which may have impacted on our assessment of cali-
bration of the original RRS. There is, as yet, no randomized evidence
that CVD risk assessment translates into CVD prevention.38
Conclusion
Whereas the performance of the original versions of four widely
used CVD risk algorithms varied substantially, simple recalibration es-
sentially equalized them and improved targeting of CVD preventive
action to clinical need. This study supports the concept of using regu-
larly recalibrated risk algorithms in routine clinical practice.
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